Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus

References

• Navarra SV, Leynes MS. Infections in systemic lupus erythematosus. Lupus. 2010;19(12):1419–24.
   PubMed Web of Science ®Google Scholar
• Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections. Scientific World Journal. 2010;10:1941–6.
   Google Scholar
• Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–17.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363(9409):600–7.
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.
   PubMed Web of Science ®Google Scholar
• Becker GJ, Waldburger M, Hughes GR, Pepys MB. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis. 1980;39(1):50–2.
   PubMed Web of Science ®Google Scholar
• Hind CR, Ng SC, Feng PH, Pepys MB. Serum C-reactive protein measurement in the detection of intercurrent infection in Oriental patients with systemic lupus erythematosus. Ann Rheum Dis. 1985;44(4):260–1.
   PubMed Web of Science ®Google Scholar
• Eberhard OK, Haubitz M, Brunkhorst FM, Kliem V, Koch KM, Brunkhorst R. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum. 1997;40(7):1250–6.
   PubMedGoogle Scholar
• Buhaescu I, Yood RA, Izzedine H. Serum procalcitonin in systemic autoimmune diseases–where are we now?Semin Arthritis Rheum. 2010;40(2):176–83.
   PubMed Web of Science ®Google Scholar
• Quintana G, Medina YF, Rojas C, Fernandez A, Restrepo JF, Rondon F, et al. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheum. 2008;14(3): 138–42.
   PubMed Web of Science ®Google Scholar
• Joo K, Park W, Lim MJ, Kwon SR, Yoon J. Serum Procalcitonin for Differentiating Bacterial Infection from Disease Flares in Patients with Autoimmune Diseases. J Korean Med Sci. 2011;26(9):1147–51.
   PubMed Web of Science ®Google Scholar
• Brunkhorst R, Eberhardt OK, Haubitz M, Brunkhorst FM. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med. 2000;26(Suppl 2):S199–201.
   Google Scholar
• Scirè CA, Cavagna L, Perotti C, Bruschi E, Caporali R, Montecucco C. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2006;24(2):123–8.
   PubMed Web of Science ®Google Scholar
• Lanoix JP, Bourgeois AM, Schmidt J, Desblache J, Salle V, Smail A, et al. Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus. 2011;20(2):125–30.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630–40.
   Google Scholar
• Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 2005;19(5):685–708.
   PubMed Web of Science ®Google Scholar
• Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–84.
   PubMed Web of Science ®Google Scholar
• Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011;52(Suppl 4):S346–50.
   Google Scholar
• Lachmann HJ, Quartier P, So A, Hawkins PN. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 2011;63(2):314–24.
   PubMedGoogle Scholar
• Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol. 1998;161(1):494–503.
   PubMed Web of Science ®Google Scholar
• Hügle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exper Rheumatol. 2008;26(3):453–6.
   PubMed Web of Science ®Google Scholar
• Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still’s disease. Ann Rheum Dis. 2009;68(6): 1074–5.
   PubMed Web of Science ®Google Scholar
• Perren A, Cerutti B, Lepori M, Senn V, Capelli B, Duchini F, et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection. 2008;36(2):163–6.
   PubMed Web of Science ®Google Scholar
• Preas HL, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during experimental endotoxemia. J Infect Dis. 2001;184(3):373–6.
   PubMed Web of Science ®Google Scholar
• Wu JY, Lee SH, Shen CJ, Hsieh YC , Yo PH, Cheng HY, et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(9):3034–42.
   PubMedGoogle Scholar
• Bador KM, Intan S, Hussin S, Gafor AH. Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus. 2012; 21(11):1172–7.
   PubMed Web of Science ®Google Scholar
• Kim HA, Jeon JY, An JM, Koh BR, Suh CH. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012;39(4):728–34.
   PubMed Web of Science ®Google Scholar
• Masiá M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005;128(4):2223–9.
   PubMed Web of Science ®Google Scholar
• Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006;32(3):469–72.
   PubMed Web of Science ®Google Scholar
• Thompson D, Bird HA. Acute phase response. In: Isenberg DA (ed), Oxford Textbook of Rheuamatology, 3rd edn. New York: Oxford University Press, 2004. pp. 473–9.
   Google Scholar